ArticleLa Radiologia medica2026
Clinical MRI-radiomics model based on support vector machine to predict the efficacy of first transarterial chemoembolization for unresectable intrahepatic cholangiocarcinoma.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- B-Mode Ultrasound Radiomics for Differentiating Benign and Malignant Small Hyperechoic Renal Masses: An Exploratory Single-Center Experience.Journal of imaging · 2026Article
- Human-AI Interaction in Interventional Radiology: A Narrative Review of Current Applications, Challenges, and Future Directions.Journal of imaging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTransarterial chemoembolization (TACE) is an effective treatment for patients with unresectable intrahepatic cholangiocarcinoma (iCCA), but tumor heterogeneity affects the efficacy of treatment. This study aimed to construct a Clinical-Radiomics (CR) model for predicting tumor response after the first TACE in patients with unresectable iCCA.
methodsA total of 107 unresectable iCCA patients who received TACE as the first treatment with available contrast-enhanced MRI (CEMRI) were retrospectively enrolled. Patients were randomly assigned to the training (N = 75) and validation cohorts (N = 32) in a 7:3 ratio. Radiomics features were extracted from CEMRI (arterial, portal venous, and delayed phases) for tumor, peritumor 5 mm, and peritumor 10 mm, respectively, and then the features were selected by random forest before constructing the radiomics model. Radiomics model score and clinical variables were analyzed using univariate and multivariate logistic regression to construct the CR model. Kaplan-Meier method was utilized to assess OS.
resultsThe radiomics model constructed based on the tumor plus peritumor 10 mm demonstrated the best performance. The CR model developed by combining with CA19.9 showed excellent performance in both the training (AUC = 0.941) and the validation cohorts (AUC = 0.903). Dividing groups based on the model predicted tumor responses, the Kaplan-Meier curves demonstrated a significant difference in OS between the two groups (P < 0.011). The main limitations of this study include the use of a single-center cohort, which lacks external validation, and the inherent characteristics of a retrospective design, leading to an unavoidable selection bias.
conclusionThe model in this study demonstrated excellent performance in predicting tumor response after first TACE in patients with unresectable iCCA. The model could support clinicians to make more scientific guidance on the treatment of patients.
Indexed as
Identifiers
41205141What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.